Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder

Telomir Pharmaceuticals, Inc.

$3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.
1 million restricted shares issued; no warrants, no discounts, no convertible features.
Proceeds to fund Telomir-1 IND submission for a rare disease indication.
Follows prior $1M investment at $7.00/share and complements $5M undrawn line of credit from same group.

item 3.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.